REG-Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November
Key Highlights
- ➤Q3 revenue $117.6M, up 21% year over year, exceeding market expectations
- ➤Joenja revenue $23.8M, up 58% year over year
- ➤Operating profit $29.9M, up 89% year over year
- ➤2026 revenue guidance tightened to $380M-$390M from $375M-$395M
- ➤CVID Phase II topline data for leniolisib expected in November 2026
Expert Statements
Kenneth Lynard, Interim Co-Chief Executive Officer of Pharming Group
“This was a quarter of execution and delivery for Pharming. We set three near-term goals – stabilizing and returning RUCONEST to revenue growth, expanding Joenja (leniolisib)’s reach, and generating Phase II data for leniolisib beyond APDS. We made strong progress on all three in the third quarter, and momentum continues into the fourth quarter.”
Kenneth Lynard, Interim Co-Chief Executive Officer of Pharming Group
“RUCONEST quarterly revenue rose 14% year-over-year to $93.8 million, supported by stabilized U.S. demand with the strongest retention in the high-burden patient segment, and continued new patient and prescribers additions. Joenja revenue grew 58% to $23.8 million with launches in Germany and Japan, higher U.S. uptake, and approval in the U.S. of new doses for children aged 4 to 11 above 27 kg with shipments commencing after quarter end. That performance translated into 21% revenue growth exceeding market expectations, an 89% increase in operating profit, and strong operating cash flow, highlighting our flexibility to invest in our priorities while staying disciplined on capital allocation.”
Leverne Marsh, Interim Co-Chief Executive Officer of Pharming Group
“We are particularly encouraged by the recent positive Phase II results for leniolisib in genetically identifiable primary immunodeficiencies, which support the role of the PI3Kδ pathway in driving immune dysregulation beyond APDS. We look forward to reporting additional data in CVID in November. Together, results from both trials will inform the path toward a potential registrational study in the broader and larger CVID population. If supported by the data, this could represent a significant opportunity for leniolisib, building on the commercial capabilities we have established with Joenja to reach more patients and realize our long-term growth ambition.”
* Third quarter 2026 total revenues increased by 21% to US$117.6 million, compared to third quarter 2025, exceeding market expectations * RUCONEST® revenue increased by 14% to US$93.8 million, compared to third quarter 2025, reflecting demand stabilization and seasonal inventory increase * Joenja® (leniolisib) revenue increased by 58% to US$23.8 million, compared to third quarter 2025, reflecting strong U.S. and international demand * Tightened 2026 total revenue guidance to US$380 million - US$390 million from prior US$375 million - US$395 million * Operating profit increased by 89% to US$29.9 million, compared to third quarter 2025 * Generated US$32.4 million in cash flow from operations in the quarter and US$24.7 million year to date, increasing cash position to US$190.9 million * Strong progress on Joenja expansion including U.S. pediatric label and launches in Germany and Japan * Announced positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation and Phase II topline data in broader CVID patient population expected in November 2026 * Pharming to host a conference call today at 13:30 CET (8:30 am EDT) Leiden, the Netherlands, October 27, 2026: Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, presents its preliminary (unaudited) financial report for the three months ended September 30, 2026.
Get started
Create a free account to read the full story.